Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $729.91, moving +1.1% from the previous trading session.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $714.57, moving +0.65% from the previous trading session.

REGN or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

REGN vs. TECH: Which Stock Is the Better Value Option?

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

by Zacks Equity Research

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update

by Zacks Equity Research

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

Company News for Jan 10, 2023

by Zacks Equity Research

Companies In The News Are: REGN, LULU, DCT, BAX.

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

by Zacks Equity Research

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

VERA Dips Despite Positive Data From IgA Nephropathy Study

by Zacks Equity Research

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?

by Zacks Equity Research

Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPGP

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

by Zacks Equity Research

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

by Zacks Equity Research

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GSEW

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

by Zacks Equity Research

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

by Zacks Equity Research

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

by Zacks Equity Research

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

Regeneron (REGN) Presents Positive Data on MM and FL Drugs

by Zacks Equity Research

Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH.

Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023.

Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GSEW

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

by Zacks Equity Research

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

by Zacks Equity Research

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

by Zacks Equity Research

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion

by Zacks Equity Research

Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.